Published in Expert Rev Vaccines on February 01, 2003
Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures. Clin Microbiol Rev (2008) 1.32
Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect Immun (2008) 1.23
Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun (2004) 1.17
Development of a Streptococcus gordonii vaccine strain expressing Schistosoma japonicum Sj-F1 and evaluation of using this strain for intranasal immunization in mice. Parasitol Res (2013) 0.75
A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing. Sci Transl Med (2012) 2.05
Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates. Hum Vaccin Immunother (2012) 1.46
Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine (2006) 1.31
Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis (2005) 1.19
Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun (2002) 1.02
Lung retinol storing cells synthesize and secrete retinoic acid, an inducer of alveolus formation. Am J Physiol Lung Cell Mol Physiol (2003) 0.96
Live, attenuated Salmonella typhimurium vectoring Campylobacter antigens. Vaccine (2005) 0.94
Recent advances in the development of live, attenuated bacterial vectors. Curr Opin Mol Ther (2005) 0.93
Vascular endothelium summary statement II: Cardiovascular disease prevention and control. Vascul Pharmacol (2006) 0.86
Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine (2007) 0.86
Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation (2007) 0.85
Microfluidic gradient formation for nanoflow chip LC. Anal Chem (2007) 0.84
Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates. Vaccine (2010) 0.82
Enterotoxigenic Escherichia coli virulence factors and vaccine approaches. Expert Rev Vaccines (2004) 0.81
Vascular endothelium summary statement VI: Research directions for the 21st century. Vascul Pharmacol (2006) 0.80
A unique approach to business strategy as a means to enable change in global healthcare: a case study. Clin Chem (2012) 0.77